| Schizophrenia

Abilify Asimtufii vs Vraylar

Side-by-side clinical, coverage, and cost comparison for schizophrenia.

Deep comparison between: Abilify Asimtufii vs Vraylar with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsVraylar has a higher rate of injection site reactions vs Abilify Asimtufii based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Vraylar but not Abilify Asimtufii, including UnitedHealthcare

Category

Abilify Asimtufii

Vraylar

At A Glance

RouteIM injection

FrequencyEvery 2 months

ClassAtypical antipsychotic

RouteOral

FrequencyDaily

ClassAtypical antipsychotic

Indications

Schizophrenia
Bipolar I disorder

Schizophrenia
Manic Disorder
Depression, Bipolar
Major Depressive Disorder

Dosing

Schizophrenia, Bipolar I disorder 960 mg IM gluteal injection once every 2 months (56 days); dose may be reduced to 720 mg if adverse reactions occur; CYP2D6 poor metabolizers: 720 mg once every 2 months.

Schizophrenia Adults: start 1.5 mg once daily; recommended 1.5-6 mg once daily (max 6 mg). Pediatric patients (13-17 years): start 0.5 mg once daily; recommended 1.5-4.5 mg once daily (max 4.5 mg).

Manic Disorder Adults: start 1.5 mg once daily, increase to 3 mg on Day 2; recommended 3-6 mg once daily (max 6 mg). Pediatric patients (10-17 years): start 0.5 mg once daily; recommended 3 mg or 4.5 mg once daily (max 4.5 mg).

Depression, Bipolar Adults: start 1.5 mg once daily; may increase to 3 mg on Day 15 (max 3 mg once daily).

Major Depressive Disorder Adults (adjunctive to antidepressants): start 1.5 mg once daily; may increase to 3 mg on Day 15 (max 3 mg once daily).

Contraindications

Known hypersensitivity to aripiprazole or any excipient

History of hypersensitivity reaction to cariprazine, including rash, pruritus, urticaria, and reactions suggestive of angioedema (e.g., swollen tongue, lip swelling, face edema, pharyngeal edema, swelling face)

Drug Interactions

1324View drug interactions

1082View drug interactions

Adverse Reactions

Most common (>=5%) Increased weight, akathisia, injection site pain, sedation

Serious Neuroleptic malignant syndrome, tardive dyskinesia, metabolic changes, orthostatic hypotension, leukopenia/neutropenia/agranulocytosis, seizures, dysphagia

Postmarketing Anaphylactic reaction, angioedema, DRESS, blood glucose fluctuation, pathological gambling, fecal incontinence, hiccups

Most common (>=5%) Extrapyramidal symptoms, akathisia, nausea, restlessness, insomnia, somnolence, dyspepsia, vomiting

Serious Neuroleptic malignant syndrome, tardive dyskinesia, increased mortality in elderly patients with dementia-related psychosis, suicidal thoughts and behaviors, cerebrovascular adverse reactions, metabolic changes, leukopenia/neutropenia/agranulocytosis, orthostatic hypotension, seizures

Postmarketing Stevens-Johnson syndrome

Pharmacology

Aripiprazole is an atypical antipsychotic whose efficacy may be mediated through partial agonist activity at dopamine D2 and serotonin 5-HT1A receptors and antagonist activity at serotonin 5-HT2A receptors; the active metabolite dehydro-aripiprazole also has affinity for D2 receptors.

Cariprazine is an atypical antipsychotic that acts as a partial agonist at central dopamine D2/D3 and serotonin 5-HT1A receptors and as an antagonist at serotonin 5-HT2A receptors; its two major active metabolites, desmethylcariprazine (DCAR) and didesmethylcariprazine (DDCAR), have in vitro receptor binding profiles similar to the parent drug.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Abilify Asimtufii